Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20452151 | 1.00 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL29580250 | 0.81 | ALDH1A1 (0.49) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL14955176 | 0.81 | ALDH1A1 (0.61) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL2076090 | 0.81 | ALDH1A1 (0.61) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL28499125 | 0.80 | ALDH1A1 (0.48) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL20452073 | 0.78 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL4159119 | 0.78 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL15525132 | 0.76 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL18453943 | 0.76 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL18453946 | 0.76 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1760082-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds | Cyclacel Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | ALDH1A1 2719/4885RAB9A 4076/4885SMN1; SMN2 2905/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | ALDH1A1 2858/4885RAB9A 4034/4885SMN1; SMN2 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.